Kelun-Biotech Announces Breakthrough Therapy Designation Granted for Sacituzumab Tirumotecan (Sac-™T) in Combination With Tagitanlimab in China for Certain Types of Non-Small Cell Lung Cancer

[
Kelun-Biotech Announces Breakthrough Therapy Designation Granted for Sacituzumab Tirumotecan (Sac-™T) in Combination With Tagitanlimab in China for Certain Types of Non-Small Cell Lung Cancer
[og_img]
https://www.investing.com/news/press-releases/kelunbiotech-announces-breakthrough-therapy-designation-granted-for-sacituzumab-tirumotecan-sact-in-combination-with-tagitanlimab-in-china-for-certain-types-of-nonsmall-cell-lung-cancer-93CH-4090031


Investing.com